Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–15 of 15 results
Advanced filters: Author: Janice M. Reichert Clear advanced filters
  • Fully human monoclonal antibodies (mAbs), which have the potential to be less immunogenic than earlier humanized and chimeric mAbs, are the most rapidly growing class of mAbs in clinical development. Here, Reichert and colleagues highlight trends in the development of human mAbs, seven of which have so far gained regulatory approval.

    • Aaron L. Nelson
    • Eugen Dhimolea
    • Janice M. Reichert
    Reviews
    Nature Reviews Drug Discovery
    Volume: 9, P: 767-774
  • Most monoclonal antibodies so far have been developed for treating cancer or immune disorders, but opportunities for the development of monoclonal antibodies to target infectious diseases seem to be increasing. Reichert and Dewitz analyse trends in the development of anti-infective monoclonal antibodies and discuss factors that influence their success.

    • Janice M. Reichert
    • Matthew C. Dewitz
    Reviews
    Nature Reviews Drug Discovery
    Volume: 5, P: 191-195
  • Monoclonal antibodies are now established as a key therapeutic modality for a range of diseases, including cancer. Reichert and Valge-Archer overview trends in the development and regulatory approval of anticancer monoclonal antibodies since 1980, with the aim of informing future research and development for this class of therapeutics.

    • Janice M. Reichert
    • Viia E. Valge-Archer
    Reviews
    Nature Reviews Drug Discovery
    Volume: 6, P: 349-356
  • Therapeutic cancer vaccines offer hope for patients for whom traditional treatments have failed, but various obstacles may impede the launch of these new agents.

    • Janice M. Reichert
    • Cherie Paquette
    Special Features
    Nature Biotechnology
    Volume: 20, P: 659-663
  • Despite initial teething problems, the number of clinically effective monoclonal antibodies is growing.

    • Janice M. Reichert
    Special Features
    Nature Biotechnology
    Volume: 19, P: 819-822
  • Although fewer antibody fragments have entered the clinic than full-length monoclonal antibodies, proof-of-concept studies for these therapeutics remain the main hurdle.

    • Aaron L Nelson
    • Janice M Reichert
    Special Features
    Nature Biotechnology
    Volume: 27, P: 331-337
  • Most monoclonal antibodies in clinical trials are owned by small biotech companies. But with blockbuster-sized revenues and approval rates higher than those for small-molecule drugs, that all may be set to change.

    • Janice M Reichert
    • Clark J Rosensweig
    • Matthew C Dewitz
    Special Features
    Nature Biotechnology
    Volume: 23, P: 1073-1078
  • Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of cytotoxic agents. The technology to develop these agents has improved in past years, but toxicity remains a key issue. This Review provides a broad overview of the recent advances and challenges in ADC development for cancer treatment.

    • Charles Dumontet
    • Janice M. Reichert
    • Alain Beck
    Reviews
    Nature Reviews Drug Discovery
    Volume: 22, P: 641-661
  • Bispecific antibodies (bsAbs) can mediate therapeutic effects beyond those of natural monospecific antibodies. This Review provides an overview of recent developments in the field of bsAbs for cancer therapy and an outlook into next-generation bsAbs in earlier stages of development.

    • Christian Klein
    • Ulrich Brinkmann
    • Roland E. Kontermann
    Reviews
    Nature Reviews Drug Discovery
    Volume: 23, P: 301-319
  • Autism is a highly heritable neurodevelopmental disorder, and yet few specific susceptibility genes have been identified to date. A linkage and association mapping study using half a million genome-wide single nucleotide polymorphisms is now described in a common set of 1,031 multiplex autism families. The linkage regions identified provide targets for rare variation screening whereas the discovery of a single novel association, SEMA5A, demonstrates the action of common variants.

    • Lauren A. Weiss
    • Dan E. Arking
    • Leena Peltonen
    Research
    Nature
    Volume: 461, P: 802-808
  • Bispecific antibodies — a large family of molecules that are designed to recognize two different epitopes or antigens — come in many formats and can have the potential for novel functionalities that are not provided by mixtures of monoclonal antibodies. This article reviews the current bispecific antibody landscape from a mechanistic perspective, including a comprehensive overview of the pipeline.

    • Aran F. Labrijn
    • Maarten L. Janmaat
    • Paul W. H. I. Parren
    Reviews
    Nature Reviews Drug Discovery
    Volume: 18, P: 585-608